The therapeutic community is buzzing with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s showing significant potential in clinical trials for treating obesity. Unlike some current weight loss solutions, retatrutide appears to offer a greater substantial loss in body size and enhance metabolic function, particu